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INTRODUCTION:  Inﬂammatory  myoﬁbroblastic  tumor  (IMT) is a rare  neoplasm  of various  anatomical  sites,
which  is histopathologically  characterized  by spindle-shaped  cells  with  myoﬁbroblastic  proliferation  and
inﬂammatory  inﬁltration.
PRESENTATION  OF  CASE:  In this  case  report,  a 37-year-old  man  presented  with nonspeciﬁc  systemic  symp-
toms,  including  abdominal  pain  and  weakness,  which  was  diagnosed  by multislice  computed  tomography
and  ultrasonography.  An 8 cm × 5  cm  × 5  cm  nodular  gray-white  ﬁrm  noninﬁltrative  mass,  which  was
well  localized  in  the  mesentery  tissues  of small  bowel,  was observed  and  the  patient  underwent  surgical
resection.
DISCUSSION:  A  review  of the  literature  on  IMT of  the small-bowel  mesentery  yielded  a small  number
of previously  described  cases.  This  tumor  most  frequently  involves  the  lungs  and  arises  most  com-
monly  in extrapulmonary  locations  such  as  the mesentery  and  omentum.  The  etiopathogenesis  and
the  clinical  course  of  the  disease  are  unclear.  The  histological  and clinical  differential  diagnosis  of  IMT
also  includes  reactive  processes  and mesenchymal  tumors  of  the  gastrointestinal  tract.  Follow-up  after
surgical  removal  documented  local  recurrence  and  metastasis.
CONCLUSION:  The  preferred  primary  treatment  is  complete  surgical  excision,  and  patients  require  close
clinicoradiological  follow-up.  In general,  cases  treated  with  complete  surgical  resection  have  a good
prognosis.
© 2014  The  Author.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Inﬂammatory myoﬁbroblastic tumors (IMTs) were originally
ermed by Bunn in 1939.1 Alternative names including plasma
ell granuloma, inﬂammatory pseudotumor, and myxoid hamar-
oma have all been used for this lesions. IMT  occurs in children
nd young adults in soft tissues and viscera in various anatomical
egions2 and shows a benign clinical course. Local recurrence or dis-
ant metastasis can develop during the course of intra-abdominal
nd retroperitoneal disease.3 This tumor most frequently arises
rom the lung and the most common extrapulmonary locations in
escending order are the abdomen (including the retroperitoneum
nd pelvis), head/neck, upper respiratory tract, trunk, extremities,4nd uterine.5 There are a very small number of IMT  in the small
ntestine mesentery cases reported in the literature.6
∗ Tel.: +90 506 3819352; fax: +90 326 2272440.
E-mail address: alikoyuncuer@hotmail.com
ttp://dx.doi.org/10.1016/j.ijscr.2014.11.054
210-2612/© 2014 The Author. Published by Elsevier Ltd. on behalf of Surgical A
http://creativecommons.org/licenses/by-nc-nd/3.0/).2. Presentation of case
2.1. Clinical data and presentation
A 37-year-old man  presented with nonspeciﬁc systemic symp-
toms, such as abdominal pain, fever, weight loss, and weakness,
to the emergency department of a state hospital. On admission
revealed clinical sign of pain in the around the epigastric, perium-
bilical region and abdominal palpable masses, rigidity. Laboratory
tests on admission showed: WBC: 11.000/mm3, Hb: 14.7 g/dl, Hct:
45.6% and normal ALT, AST levels, hepatitis B, HCV, HIV viral
markers. Case had presented to the emergency department with
suspicious for a malignancy, hence a preoperative biopsy was  not
performed. Abdominal ultrasonography and computer tomogra-
phy (CT) imaging showed a solid mass in the right intra-abdominal
region. The clinical impression was that the lesion represented
tumor. Intraoperatively, a large tumor was  found involving the
small bowel mesentery and no extension or pressure to adja-
cent organs. No intraoperative complications were observed. Our
patient underwent an without any complications postoperative
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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nFig. 1. (A, B) Gross features: the macroscopic appearance of i
ourse, the patient was discharged on the 7th postoperative day.
he patient underwent segmental small intestine resection.
.2. Histopathological ﬁndings
.2.1. Macroscopic appearance
The specimen was collected from the small bowel and consisted
f a segment of intestine measuring 20 cm in length × 2.5 cm in
verage diameter (2 cm circumference proximal margin, 1.5-cm
ircumference distal margin) after ﬁxation in 10% neutral buffered
ormalin. A serial section of the small bowel specimen of patient
id not reveal inﬁltrative tumors in the intra-luminal compart-
ent. Gross ﬁndings of the nonperitonealized perimuscular tissue
r mesentery tissues showed nodular features and gray-white ﬁrm
oninﬁltration, and a well-localized, well-demarcated smooth dis-
rete mass measuring 8 cm × 5 cm × 5 cm.  The cut surface section
f the lesion had a diffuse gray or yellow appearance. Macroscopic
umor perforation, necrosis, hemorrhage, calciﬁcation, and ulcera-
ion were not identiﬁed (Fig. 1A and B).
.2.2. Microscopic features
Histologically, the tumor appeared to predominantly consist of
lasma cells, lymphocytes, and plump- or spindle-shaped cells of
yoﬁbroblasts. The tumor had a prominent storiform and fascicu-
ar pattern with collagenized areas and lymphocytes; plasma cells
ormed small aggregates or nodules of lymphoid background. Mito-
is, necrosis, and myxoid background were not present. The tumor
ells were positive for smooth muscle actin and vimentin and neg-
tive for antibodies to CD117, S100, CD34, desmin, CD30, and Ki-67
Fig. 2A–D).
. Discussion
Previously described in the literature as inﬂammatory pseudo-
umor, the current term for the condition is IMT.7 IMT  lesions are
omposed entirely of spindle cells with characteristic of cells of
yoﬁbroblastic origin.8 In this setting, IMT  occurs in various age
roups, and is slightly more common in women than in men.2 Cofﬁn
t al.4 reported a mean age of 9.7 years (range, 3 months–46 years)
or IMT  patients. The disease appears to results from diverse etiolo-
ies, including Epstein–Barr virus, human herpes virus 8, elevated
evels of cytokines (i.e., interleukin-6),9 reperative, postoperative,
nd mycobacterial infections,2 and post-traumatic injury, to name
 few.10 IMT  occurred in our case even without a history of
bdominal trauma or surgery. Using immunocytochemical tech-
iques, Freeman et al.11 reported anaplastic lymphoma kinasematory myoﬁbroblastic tumor in the small bowel specimen.
(ALK) 1 in the urinary bladder of IMT  patients (eight/nine cases).
Whereas, molecular studies have demonstrate rearrangements in
chromosome 2p23, and ALK gene rearrangements has been iden-
tiﬁed in approximately 33–67% of IMT  cases. Fluorescence in situ
hybridization analysis was  performed to accurately identify ALK
rearrangements.12 The clinical presentation differs depending on
the anatomical regions examined. Clinically, intra-abdominal or
retroperitoneal tumors present as palpable masses, with symp-
toms of abdominal pain and weight loss that can be obstructive,13
and diarrhea in children.10 Moreover, lung tumors present as dys-
pnea, pain, fever, and cough.14 Ntloko et al.10 reported that the
most common symptoms/signs of IMT  are abdominal pain and
change in intestinal habits; however, our case presented with non-
speciﬁc symptoms such as acute abdominal pain and no vomiting
or intestinal obstruction. The predominant extrapulmonary IMT
regions involve include the mesentery and omentum.3 However,
the gastroesophageal junction, colon, rectum, appendix,15 small
bowel, gastric wall16 and rarely, other regions of the gastrointesti-
nal tract may  be implicated. Our case presented with an ileojejunal
mass of mostly mesenteric or subserosal adipose tissue growth. In
general, masses appear on gross examination of a resection speci-
men  as nodular and lobular, myxoid background sometimes with
features of necrosis and hemorrhage.12 These lesions measure from
2 to 20 cm in largest dimension2 and the mean tumor size reported
in the literature is 8 cm.8 A recent study of IMT  described three
major histological characteristics. The ﬁrst mainly involves inﬂam-
matory cells and has myxoid stroma. The second shows compact
proliferation of spindle-shaped cells. The third contains abundant
collagen in a plate-like pattern.17 Yamamoto et al.18 have reported
lymphoplasmacytic inﬁltration containing germinal center in the
lymphoid follicles in the latter feature. In our case, IMT displayed
extensive lymphoid follicles, and microscopically, a mixture of
inﬂammatory inﬁltrates composed largely of lymphocytes and
plasma cells; few eosinophils are present. Atypical cells, mitosis,
myxoid stroma, and necrosis were not present, but small clusters
were present in neuronal hyperplasia in the ﬁbrous stroma. The
differential diagnosis of IMT  includes reactive/reparative lesions
and mesenchymal tumors of the gastrointestinal tract including
granulation tissues and nodular fasciitis in reactive processes,4
spindle cell sarcomas, spindle cell melanomas, and sarcomatoid
carcinomas, dedifferentiated liposarcoma, gastrointestinal stro-
mal  tumors, Hodgkin’s lymphoma, inﬂammatory ﬁbroid polyp,
and other ﬁbro-inﬂammatory processes (or pseudoneoplasms) and
malignant tumors.2,19 Approximately 25% of patients with extra-
pulmonary IMT  have recurrence, and distant metastasis (rate: <5%)
has been reported. The principal therapy in patients with IMT  is
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C)  High-power magniﬁcation demonstrating the presence of tumor consist spindle
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urgical resection, and in some situations, corticosteroids and non-
teroidal anti-inﬂammatory drugs may  be useful.4 In our case, after
pproximately one month of follow-up, there was no evidence of
ymptoms or recurrent disease.
. Conclusion
Clinical behavior of IMT  are similar to tumors of uncertain malig-
ant potential. The tumors are generally biologically benign lesions
hat do not present a high risk of local recurrence and distant
etastases. The preferential method of treatment is complete sur-
ical excision of the lesion, and close clinicoradiological follow-up collagenized areas and chronic inﬂammatory cells (Hematoxylin and Eosin, 40×).
shaped of myoﬁbroblasts, mature plasma cells and lymphocytes (Hematoxylin and
ive). (E) Immunohistochemically positive for vimentin (40× objective).
with ultrasonography, chest roentgenography, and abdominal CT
imaging is necessary. Previous studies report a considerably better
prognosis in IMT  patients with this method of treatment.
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